Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics.
Insilico Medicine Inc. has reported the development of ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors described as useful for the treatment of cancer.
Sanofi SA has prepared and tested isoxazolidines acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. As such, they are reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and incontinentia pigmenti.
Research at Biomea Fusion Inc. has led to the development of GTPase KRAS (G12C mutant) and (G12D mutant) inhibitors potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Two Vigil Neuroscience Inc. patents describe triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson’s, Alzheimer’s and Nasu-Hakola diseases.
Researchers from Beijing Corregene Biotechnology Co. Ltd. presented preclinical data for CRTE7A2-01, a cell therapy candidate consisting of human T cells expressing T-cell receptors (TCRs) specific for HLA-A*02:01-restricted HPV16 E7 antigen.
Scientists from the Hospital for Sick Children Research Institute and collaborators have reported the application of a multispecific, multiaffinity antibody (Multabody, MB) platform derived from the human apoferritin protomer to enable the multimerization of antibody fragments against SARS-CoV-2. These MBs showed high potency to neutralize SARS-CoV-2 even at lower concentrations than their corresponding MAb counterparts.
Defence Therapeutics Inc. has contracted Transbiotech Biotechnology Research and Transfer Center to test the potency of the company’s cellular anticancer ARM vaccine in animals with pre-established pancreatic tumors.
The pathogenesis of chronic pancreatitis (CP) is complex and involves interactions among different cell types, including pancreatic acinar, ductal and stellate cells (PSC). Researchers from Calcimedica Inc. and the University of Szeged set out to assess the pathogenic pathways in these cells as well as evaluate the potential of the novel calcium release-activated calcium channel protein 1 (Orai1) inhibitor CM-5480 as a potential treatment for CP.
RSS
